Vertex Pharmaceuticals stock gains 1.63 percent on October 7

Published on 10/07/2026 at 17:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vertex Pharmaceuticals stock traded at USD 510.51 by 10:59 a.m. ET on October 7, 2026. Second-quarter revenue reached USD 3.33 billion, up 12.5 percent year over year.

Aquarellbild der Boston-Skyline mit Segelbooten am Hafen im warmen Licht — Vertex Pharma US92532F1003 zeigt die Boston Skyline am Wasser in weicher Aquarell-Malerei-Optik mit Segelbooten, Illustration mit AI erstellt.

Vertex Pharmaceuticals (ISIN US92532F1003) was trading at USD 510.51 on Nasdaq at 10:59 a.m. ET on October 7, 2026, up 1.63 percent from the prior close. The move keeps the biotechnology company within reach of its 52-week high as investors weigh recent revenue growth against pipeline execution.

Q2 revenue beat expectations

According to MarketBeat on October 3, 2026, Vertex generated USD 3.33 billion in second-quarter revenue, up 12.5 percent year over year and above the USD 3.23 billion consensus. Adjusted earnings per share came in at USD 4.73, narrowly below the USD 4.74 estimate, creating a split operating picture rather than a uniform earnings beat.

The revenue result is important because it shows that Vertex is still expanding beyond its established cystic fibrosis franchise. The earnings miss, however, leaves execution and product mix as the nearer-term test for the stock.

Consensus target sits above price

MarketBeat reported an average Moderate Buy rating from 23 analysts, with targets ranging from USD 550.00 to USD 615.00 and an average of USD 575.13. Against the October 7 price of USD 510.51, that average target lies 12.7 percent above the stock.

UBS raised its target from USD 585.00 to USD 615.00 while maintaining a Buy rating, as Investing.com reported on September 28, 2026. The firm tied its view to upcoming Phase III data for inaxaplin, Vertex's oral treatment for APOL1-mediated kidney disease.

Pipeline data drive valuation

Vertex announced positive Phase 2b AMPLIFIED results for inaxaplin and completion of enrollment in the Phase 2/3 AMPLITUDE study on September 22, 2026, according to MarketScreener. The company said the interim analysis is planned for early 2027 after the relevant treatment cohort reaches 48 weeks.

The counter-factor is clinical execution. UBS said the Phase III interim readout must show statistically significant results for both proteinuria and the estimated glomerular filtration rate slope, according to Investing.com.

Market cap reaches USD 129.6 billion

Vertex's market capitalization was USD 129.6 billion on October 7, 2026. The 52-week range of USD 402.58 to USD 560.25 places the stock 8.9 percent below its yearly high, while the October 7 intraday range ran from USD 503.94 to USD 510.79.